Hill Jaime
Known title: President, Building MaterialsCIK: 0002069377
Hill Jaime's purchase track record
How the stock did after each of Hill Jaime's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
4
of 5 since August 8, 2025
Stock higher 6 months later
75%
3 months: 50%
Median 6-month return
+14.0%
3 months: -1.2%
Beat the S&P 500
50%
median +6.2% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/11/2026 | AMRZ | $71K | pending | pending | — |
| 3/9/2026 | AMRZ | $295K | -12.9% | -28.1% | +12.9% |
| 11/4/2025 | AMRZ | $203K | +5.9% | +5.5% | +7.2% |
| 8/22/2025 | AMRZ | $25K | -6.0% | +27.1% | +6.8% |
| 8/8/2025 | AMRZ | $394K | +3.7% | +22.5% | +8.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| AMRZ | ▲ Buy | Open Market | 1,500 | $71K | 8/11/2026 | View on chart |
| AMRZ | ▲ Buy | Open Market | 1,000 | $57K | 3/12/2026 | View on chart |
| AMRZ | ▲ Buy | Open Market | 1,000 | $59K | 3/11/2026 | View on chart |
| AMRZ | ▲ Buy | Open Market | 3,184 | $179K | 3/9/2026 | View on chart |
| AMRZ | ▲ Buy | Grant | 6,385 | $0 | 2/27/2026 | View on chart |
| AMRZ | ▼ Sell | Tax Withholding | 1,928 | $125K | 2/27/2026 | View on chart |
| AMRZ | ▲ Buy | Open Market | 4,000 | $203K | 11/4/2025 | View on chart |
| AMRZ | ▲ Buy | Open Market | 500 | $25K | 8/22/2025 | View on chart |
| AMRZ | ▲ Buy | Open Market | 4,000 | $208K | 8/15/2025 | View on chart |
| AMRZ | ▲ Buy | Open Market | 4,000 | $186K | 8/8/2025 | View on chart |
| AMRZ | ▼ Sell | Other | 5,601 | $0 | 6/23/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
JP Morgan cuts Amrize price target to $48, maintains Neutral
JP Morgan has lowered its price target for Amrize to $48 while keeping a Neutral rating. This move comes as the company prepares to announce its third-quarter 2026 financial results. Recent reports also highlight the firm's regional scale and pricing power, though the current analyst target sits below the average consensus of $47.20.
JP Morgan cuts Amrize price target to $48, maintains Neutral. JP Morgan has lowered its price target for Amrize to $48 while keeping a Neutral rating. This move comes as the company prepares to announce its third-quarter 2026 financial results. Recent reports also highlight the firm's regional scale and pricing power, though the current analyst target sits below the average consensus of $47.20.